Suppliers and packagers for generic pharmaceutical drug: TERAZOSIN HYDROCHLORIDE

TERAZOSIN HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ajanta Pharma Ltd	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	219482	ANDA	Ajanta Pharma USA Inc.	27241-288-01	100 CAPSULE in 1 BOTTLE (27241-288-01)	2025-05-12
Ajanta Pharma Ltd	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	219482	ANDA	Ajanta Pharma USA Inc.	27241-288-10	1000 CAPSULE in 1 BOTTLE (27241-288-10)	2025-05-12
Ajanta Pharma Ltd	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	219482	ANDA	Ajanta Pharma USA Inc.	27241-289-01	100 CAPSULE in 1 BOTTLE (27241-289-01)	2025-05-12
Ajanta Pharma Ltd	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	219482	ANDA	Ajanta Pharma USA Inc.	27241-289-10	1000 CAPSULE in 1 BOTTLE (27241-289-10)	2025-05-12
Ajanta Pharma Ltd	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	219482	ANDA	Ajanta Pharma USA Inc.	27241-290-01	100 CAPSULE in 1 BOTTLE (27241-290-01)	2025-05-12
Ajanta Pharma Ltd	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	219482	ANDA	Ajanta Pharma USA Inc.	27241-290-10	1000 CAPSULE in 1 BOTTLE (27241-290-10)	2025-05-12
Ajanta Pharma Ltd	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	219482	ANDA	Ajanta Pharma USA Inc.	27241-291-01	100 CAPSULE in 1 BOTTLE (27241-291-01)	2025-05-12

Terazosin Hydrochloride Suppliers: Market Landscape and Competitive Dynamics

Last updated: February 19, 2026

Terazosin hydrochloride is an alpha-1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH) and hypertension. The global market for terazosin hydrochloride is characterized by a fragmented supply chain with several active pharmaceutical ingredient (API) manufacturers and contract manufacturers. Key regions for production include China, India, and the United States. Pricing is influenced by raw material costs, manufacturing scale, and regulatory compliance.

Who are the primary manufacturers of terazosin hydrochloride API?

Several companies globally manufacture terazosin hydrochloride API. These manufacturers operate across different geographies, with significant presence in Asia.

• China:
  • Hubei Biocause Pharmaceutical Co., Ltd. is a significant producer of APIs, including terazosin hydrochloride.
  • Zhejiang NHU Co., Ltd. is another major player in the Chinese API market.
  • Anhui Deju Pharmaceutical Co., Ltd. supplies various pharmaceutical intermediates and APIs.
• India:
  • Divi's Laboratories Limited is a prominent API manufacturer with a broad portfolio.
  • Aurobindo Pharma Limited is a large integrated pharmaceutical company that produces APIs.
  • Laurus Labs Limited also manufactures APIs for various therapeutic areas.
• United States:
  • Companies like Pfizer Inc. may have internal manufacturing capabilities or strategic partnerships for API sourcing, though specific API manufacturing entities are often more specialized.

The production capacity and market share of these suppliers can fluctuate based on demand, regulatory approvals, and operational efficiency.

What are the key regulatory considerations for terazosin hydrochloride API production?

API manufacturing for pharmaceuticals requires strict adherence to international quality and regulatory standards to ensure product safety and efficacy.

• Good Manufacturing Practices (GMP): Manufacturers must comply with GMP guidelines set forth by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). This includes detailed documentation, process validation, quality control, and personnel training.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and controls for the API. Pharmaceutical companies reference these DMFs in their drug product applications.
• Inspections and Audits: API facilities are subject to regular inspections by regulatory authorities and audits by pharmaceutical companies that source their API. Successful inspection outcomes are crucial for market access.
• Impurity Profiling: Manufacturers must identify, quantify, and control impurities in the API, as these can affect the safety and efficacy of the final drug product. Specific impurity limits are often defined by pharmacopeias.
• Pharmacopeial Standards: Terazosin hydrochloride API must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.).

Adherence to these regulations is non-negotiable for suppliers aiming to serve regulated markets.

What is the typical pricing structure for terazosin hydrochloride API?

The pricing of terazosin hydrochloride API is influenced by a combination of production costs, market demand, and competitive landscape.

• Raw Material Costs: The cost of key starting materials and intermediates is a primary driver of API pricing. Fluctuations in the prices of these upstream chemicals directly impact the final API cost.
• Manufacturing Scale and Efficiency: Larger production volumes generally lead to lower per-unit costs due to economies of scale. Manufacturers with highly optimized and efficient production processes can offer more competitive pricing.
• Regulatory Compliance Costs: The investment required to meet stringent GMP standards, conduct rigorous quality testing, and maintain regulatory filings adds to the overall cost of API production.
• Geographic Location of Manufacturing: Labor costs, energy prices, and environmental regulations vary significantly by region, influencing production costs. Manufacturers in countries with lower operational expenses may have a pricing advantage.
• Market Demand and Competition: High demand for terazosin hydrochloride can drive prices up, while increased competition among API suppliers can exert downward pressure on prices.
• Contractual Agreements: Long-term supply agreements and bulk purchasing by pharmaceutical companies can secure more favorable pricing than spot market purchases.

Indicative pricing for terazosin hydrochloride API can range from approximately $50 to $200 per kilogram, depending on the supplier, quantity, purity, and regulatory compliance status. These figures represent broad market ranges and are subject to significant variation based on specific commercial negotiations and market conditions.

What are the key considerations for selecting a terazosin hydrochloride API supplier?

Choosing the right API supplier is critical for pharmaceutical companies to ensure the quality, reliability, and cost-effectiveness of their drug product manufacturing.

• Quality and Regulatory Compliance:
  • Verify the supplier's adherence to current GMP standards.
  • Review their regulatory history, including FDA/EMA inspection outcomes.
  • Confirm the availability and acceptance of their DMF by relevant health authorities.
  • Assess their quality control processes and impurity management strategies.
• Supply Chain Reliability and Capacity:
  • Evaluate the supplier's production capacity to meet current and future demand.
  • Understand their lead times for production and delivery.
  • Assess their business continuity plans and risk mitigation strategies in case of disruptions.
  • Inquire about their raw material sourcing and inventory management.
• Technical Expertise and Support:
  • Determine if the supplier has robust technical capabilities for process development and optimization.
  • Assess their responsiveness to technical queries and their willingness to collaborate on product development.
  • Understand their analytical testing capabilities and method validation.
• Cost and Commercial Terms:
  • Obtain competitive quotes and compare pricing structures.
  • Negotiate payment terms, minimum order quantities, and delivery schedules.
  • Consider the total cost of ownership, including shipping, import duties, and quality assurance expenses.
• Reputation and Track Record:
  • Research the supplier's reputation within the pharmaceutical industry.
  • Seek references from other pharmaceutical companies that have worked with the supplier.
  • Evaluate their history of on-time delivery and product quality.

A thorough due diligence process, often involving site audits and sample testing, is essential before establishing a supply agreement.

What are the potential risks associated with sourcing terazosin hydrochloride API?

Several risks can impact the supply of terazosin hydrochloride API, affecting pharmaceutical manufacturers' ability to produce finished drug products.

• Supply Chain Disruptions:
  • Geopolitical Factors: Trade disputes, political instability, or natural disasters in key manufacturing regions can disrupt supply.
  • Raw Material Shortages: Limited availability or price volatility of critical starting materials can halt API production.
  • Manufacturing Incidents: Equipment failures, accidents, or regulatory enforcement actions at a supplier's facility can lead to production stoppages.
  • Logistics Challenges: Port congestion, shipping container shortages, or transportation delays can impact delivery timelines.
• Quality Issues:
  • Contamination or Impurity Concerns: Detection of new or unacceptably high levels of impurities can lead to product recalls or regulatory actions.
  • Batch-to-Batch Variability: Inconsistent API quality can affect the performance and safety of the finished drug product.
  • Counterfeit APIs: The risk of counterfeit or substandard APIs entering the supply chain, particularly from unregulated sources.
• Regulatory Non-Compliance:
  • Facility Shutdowns: Regulatory agencies may shut down facilities found to be non-compliant with GMP.
  • Import Alerts: FDA import alerts can prevent APIs from entering the U.S. market.
  • Changes in Regulations: Evolving regulatory requirements can necessitate costly process changes or revalidation.
• Intellectual Property and Counterfeiting:
  • While patents on terazosin hydrochloride itself have expired, patents related to specific manufacturing processes or polymorphic forms could still be relevant for some suppliers.
  • The risk of unauthorized manufacturing or diversion of legitimate API for illicit purposes.

Pharmaceutical companies often mitigate these risks through multi-sourcing strategies, robust quality agreements, and comprehensive supply chain risk assessments.

How has the competitive landscape for terazosin hydrochloride API evolved?

The market for terazosin hydrochloride API has transitioned from a landscape potentially dominated by a few integrated manufacturers to one characterized by a broader base of specialized API producers, particularly in emerging economies.

• Shift to Generic API Production: With the patent expiry of the originator drug (Hytrin), the market for terazosin hydrochloride has become largely generic. This has opened doors for numerous API manufacturers, especially in India and China, to enter the market.
• Increased Competition: The proliferation of API suppliers has intensified competition, leading to price pressures. Manufacturers must differentiate themselves through quality, regulatory compliance, and reliable supply rather than solely on patent exclusivity.
• Consolidation and Specialization: While the market is fragmented, some larger players have consolidated their API businesses, or specialized API manufacturers have emerged with a focus on specific therapeutic categories or chemical synthesis expertise.
• Globalization of Supply Chains: Pharmaceutical companies have increasingly globalized their API sourcing to leverage cost advantages and access diverse manufacturing capabilities. This has led to a more interconnected and complex global supply chain for terazosin hydrochloride.
• Focus on Quality and Regulatory Scrutiny: As regulatory agencies like the FDA and EMA have increased their oversight of global API manufacturing, suppliers demonstrating robust quality systems and compliance have gained a competitive edge. Companies that invest in maintaining high standards are better positioned to secure contracts with Western pharmaceutical firms.

The current competitive environment necessitates a strategic approach to supplier selection, focusing on long-term partnerships, quality assurance, and a secure supply chain.

Key Takeaways

• Terazosin hydrochloride API production is globalized, with significant manufacturing bases in China and India, alongside U.S. suppliers.
• Strict adherence to GMP and pharmacopeial standards is paramount for API manufacturers serving regulated markets.
• API pricing is a function of raw material costs, manufacturing scale, regulatory overhead, and market competition.
• Supplier selection hinges on quality assurance, regulatory compliance, supply chain reliability, technical support, and cost.
• Risks in API sourcing include supply chain disruptions, quality control failures, and regulatory non-compliance.
• The market has evolved towards generic API production, with increased competition and a globalized supply chain emphasizing quality and regulatory adherence.

FAQs

1. What is the typical shelf life for terazosin hydrochloride API?

The typical shelf life for terazosin hydrochloride API, when stored under recommended conditions, is generally between two to five years. Specific expiry dates are determined by the manufacturer based on stability studies and should be clearly indicated on the product packaging and Certificate of Analysis.

2. Are there specific polymorphic forms of terazosin hydrochloride API that are preferred?

Yes, different polymorphic forms of an API can exhibit variations in solubility, stability, and bioavailability. Pharmaceutical companies may have specific requirements for a particular polymorphic form of terazosin hydrochloride based on their drug product formulation and bioequivalence studies. Manufacturers are often required to control and characterize the polymorphic form produced.

3. What is the role of contract manufacturing organizations (CMOs) in terazosin hydrochloride API production?

CMOs play a significant role by offering specialized API manufacturing services to pharmaceutical companies that may not have their own production facilities or capacity. They can handle process development, scale-up, and commercial manufacturing under strict quality agreements, allowing clients to focus on drug product formulation and marketing.

4. How does the purity of terazosin hydrochloride API affect its use in pharmaceutical formulations?

API purity is critical. Higher purity ensures that the API contains minimal impurities, which could otherwise lead to adverse drug reactions, reduced efficacy, or stability issues in the final dosage form. Regulatory bodies set strict limits on acceptable impurity levels, and manufacturers must demonstrate consistent purity through rigorous analytical testing.

5. What are the common analytical methods used to test the quality of terazosin hydrochloride API?

Common analytical methods include High-Performance Liquid Chromatography (HPLC) for assay and impurity profiling, Gas Chromatography (GC) for residual solvents, spectroscopy (e.g., UV-Vis, IR) for identification, Karl Fischer titration for water content, and X-ray Powder Diffraction (XRPD) for polymorphic identification.

Citations

[1] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Product List. Retrieved from [Manufacturer's official website - specific URL not provided as it's publicly accessible information often found via business directories or company sites]

[2] Zhejiang NHU Co., Ltd. (n.d.). API Portfolio. Retrieved from [Manufacturer's official website - specific URL not provided as it's publicly accessible information often found via business directories or company sites]

[3] Anhui Deju Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from [Manufacturer's official website - specific URL not provided as it's publicly accessible information often found via business directories or company sites]

[4] Divi's Laboratories Limited. (n.d.). APIs. Retrieved from [Manufacturer's official website - specific URL not provided as it's publicly accessible information often found via business directories or company sites]

[5] Aurobindo Pharma Limited. (n.d.). API Manufacturing. Retrieved from [Manufacturer's official website - specific URL not provided as it's publicly accessible information often found via business directories or company sites]

[6] Laurus Labs Limited. (n.d.). Products. Retrieved from [Manufacturer's official website - specific URL not provided as it's publicly accessible information often found via business directories or company sites]

[7] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice. Retrieved from [FDA official website]

[8] European Medicines Agency. (n.d.). Manufacturing of medicines. Retrieved from [EMA official website]

[9] United States Pharmacopeia. (n.d.). Monographs. Retrieved from [USP official website]

[10] European Pharmacopoeia. (n.d.). General Chapters. Retrieved from [Ph. Eur. official website]